|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
KRAS is the most commonly mutated oncogene in human cancers, such as pancreatic cancers, colon cancers, and lung cancers.
|
31456522 |
2019 |
|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
PC significantly inhibited the viability of KRAS mutant pancreatic cancer cells (PANC-1 and MiaPaCa-2) in a dose-dependent manner; however, it did not affect the wild type KRAS pancreatic cancer cells (BxPC-3).
|
30716311 |
2019 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recurrent activating point mutations in KRAS are critical drivers in pancreatic cancer and have been attributed to resistance to anti-epidermal growth factor receptor therapy in colorectal cancer.
|
30472330 |
2019 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
K-Ras mutations are widespread in PC cases (90%), with mutations detectable as early as pancreatic intraepithelial neoplasias and in later metastatic stages alike; therefore, these mutations in K-Ras are obvious drivers and potential targets for PC therapy.
|
29199014 |
2019 |
|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
The oncogene KRAS not only promotes the tumorigenesis of pancreatic cancers but also is required for the malignant progression and metastasis of these cancers.
|
30347501 |
2019 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Further workup revealed that circulating tumor-derived DNA and liver metastases originated from a synchronous KRAS-mutated cancer of the pancreas.
|
31134762 |
2019 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Targeting EphA2 with miR-124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer.
|
30604411 |
2019 |
|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) has been depicted as a therapeutic target in pancreatic cancer for many years.
|
28639199 |
2019 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We conclude that EGFR-targeted RIT with panitumumab-MCP-<sup>177</sup>Lu was able to overcome resistance to panitumumab in KRAS mutant PANC-1 tumors in NRG mice and may be a promising approach to treatment of PnCa in humans.
|
30589553 |
2019 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.
|
31311847 |
2019 |
|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.
|
29229669 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.
|
30041673 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Together, our data suggest that matrine can suppress the growth of KRAS-mutant pancreatic cancer by inhibiting autophagy-mediated energy metabolism.
|
29791786 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our databank of non‑coding RNAs (mainly miRNAs and lncRNAs) that regulate KRAS is expected to greatly enhance our understanding of KRAS regulation-associated tumorigenesis and may aid in the development of gene therapies for pancreatic cancer.
|
30221677 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Remarkably, in 3D spheroid cancer cell cultures, some triple action compounds showed an antitumor potency up to 50-fold higher than cisplatin against a KRAS mutated pancreatic cancer cell line (PSN-1 cells).
|
29780561 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, by identifying these mechanisms, our work also provides mechanistic directions to develop combination strategies that can help enforce the efficacy of KRAS inhibitors.<b>Significance:</b> These results call into question the degree to which pancreatic cancers are addicted to KRAS by illustrating adaptive nongenetic and nontranscriptional mechanisms of resistance to Kras blockade, with implications for the development of KRAS inhibitors for PDAC treatment.<i></i>.
|
29279356 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex.
|
29851957 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
We validated this homogeneous process by evaluating the effects of well-characterized anticancer agents against four patient-derived pancreatic cancer KRAS mutant-associated primary cells, including cancer-associated fibroblasts.
|
29673279 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Here we demonstrate that the CRISPR-Cas13a system can be engineered for targeted therapy of mutant KRAS in pancreatic cancer.
|
29870774 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although KRAS mutations are one of the major driver mutations in PDA, KRAS mutation alone is not sufficient to induce invasive pancreatic cancer in mice model.
|
29670173 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Through the PDC, we investigated the therapeutic impact of sorafenib alone, LEE001 alone and the combination of sorafenib and LEE001 in KRAS mutant PC.
|
30271501 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study.
|
29360815 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
Given the high degree of evolutionary conservation in the K-RAS/SIAH signaling pathway, an anti-SIAH-based anti-PDAC therapy will synergize with covalent K-RAS inhibitors and direct K-RAS targeted initiatives to control and eradicate pancreatic cancer in the future.
|
29757973 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
As KRAS mutation is prevalent in pancreatic cancer, the efficacy of these ligands against human pancreatic ductal carcinoma cell line PANC-1 and MiaPaCa2 were examined.
|
30223034 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Detection of KRAS or p53 mutation in plasma is not an effective screening tool for pancreatic cancer because accumulation of multiple mutations is required for malignant transformation in the pancreas.
|
29303908 |
2018 |